结核病诊断市场按产品、技术、检测类型、最终用户和应用划分－2025-2032年全球预测

预计到 2032 年，结核病诊断市场规模将达到 49.3 亿美元，复合年增长率为 5.65%。

引言部分重点介绍了影响整个医疗保健系统结核病诊断和决策的当代临床、实验室和政策因素。

结核病（TB）是一项重大的公共卫生挑战，需要临床、实验室和公共卫生系统之间协调一致的诊断应对措施。诊断领域错综复杂，涵盖各种技术、检体处理流程和最终用户，每个环节都会影响临床决策和病患预后。随着诊断工具的不断发展，从临床医生到参考实验室的相关人员必须应对不断变化的法规环境、供应链动态以及疾病流行病学的演变。因此，对当前趋势和策略意义进行简明扼要的总结将有助于更明智地分配资源和技术应用选择。

本执行摘要整合了影响诊断实务和采购的各项交叉主题，重点阐述了技术进步、营运瓶颈和政策驱动因素。它还着重强调了影响采购週期和临床效用，涵盖从耗材到设备、从分子平台到非分子平台等各个方面。本书将这些洞见融入当代临床优先事项，为负责大规模部署诊断并将其整合到更广泛的医疗服务路径中的领导者提供参考。摘要，本书从描述性背景入手，逐步深入到策略性启示，阐述了各机构如何在保持以患者为中心的治疗效果和系统韧性的同时，使投资与不断变化的诊断需求保持一致。

快速的分子创新、数位影像技术的进步以及系统互通性如何重塑结核病诊断和临床路径

结核病诊断领域正经历一系列变革性转变，其驱动力包括技术创新、不断变化的临床重点以及现代化诊疗实践。分子技术，特别是快速核酸增幅检查和基因分型检测，正从专业标准化走向更分散的应用，从而缩短了检测结果的获取时间，并有助于更早做出治疗决策。同时，非分子诊断方法，例如数位放射成像，在人工智慧和改进的免疫分析技术的辅助下，不断完善病例发现和分诊策略，从而构建出更多层次的诊断路径，以平衡敏感性、特异性和资源限制。

同时，整合趋势正在改变医疗保健系统内诊断服务的提供方式。实验室越来越重视与电子健康记录和实验室资讯系统的互通性，而照护现场优先考虑易用性和远端监测的连接性。这一转变与政策和项目的调整相辅相成，这些调整优先考虑快速检测抗药性菌株、改善患者与医疗服务的衔接，并支持在高负担人群中主动发现病例。因此，医疗服务提供者和采购团队面临着有关技术配置、培训需求和长期营运永续性的新决策，这促使他们重新评估投资重点和实施蓝图。

评估美国关税于2025年生效后对诊断采购、供应链韧性和供应商策略的累积营运和采购影响。

2025年关税及贸易政策调整的实施对诊断价值链各环节的筹资策略、供应商选择和零件采购都产生了影响。关税压力往往导致进口设备和耗材的到岸成本上升，迫使实验室管理人员和采购负责人重新审视供应商合约并考虑其他筹资策略。为此，许多相关人员寻求区域供应商、签订长期供应商协议并增加库存缓衝，以降低成本波动和运输延误的风险。

此外，由于製造商寻求尽可能减少贸易壁垒的影响，关税可能会加速供应商多元化和本地化生产。从长远来看，这种转变可能会改变供应链，并鼓励在更靠近需求中心的地方投资生产能力。同时，监管机构和采购方越来越重视供应链透明度、合约弹性和紧急应变计画，以确保诊断服务的连续性。综上所述，这些发展凸显了采购团队和企业负责人在确保紧急时应对计画获得临床效能和诊断工具的同时，将贸易政策情境纳入营运规划的必要性。

将产品类型、技术等级、测试目的、最终用户偏好和临床用途与筹资策略和营运策略联繫起来的详细細項分析

了解市场细分对于使产品策略与临床效用和采购週期保持一致至关重要。按产品类型划分，市场涵盖耗材和仪器。耗材包括套件和试剂，其重复使用特性决定了持续的采购决策和低温运输物流。仪器则需要资本规划、安装和维护，因此采购选择通常反映了长期的临床工作流程和服务协议。这种产品层面的差异化也会影响供应商合约、保固制度和培训承诺。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 整合基于 CRISPR 的照护现场技术以快速检测结核病
• 将人工智慧增强影像技术应用于结核病筛检中痰涂片的自动分析
• 扩大携带式分子诊断平台规模，以便在偏远地区进行社区结核病筛检
• 全球推广多重核酸增幅检查用于检测抗药性结核病
• 次世代定序的出现，为全面的抗药性分析和流行病学追踪提供了可能。
• 开发一种基于呼吸的挥发性有机化合物感测器，用于在护理点进行非侵入性结核病筛检
• 将具备诊断功能的数位健康平台整合到结核病即时监测和管理中
• 政府补贴计画促进高负担地区采用快速分子结核病检测方法
• 诊断设备製造商与非政府组织建立策略伙伴关係，加速普及低成本结核病检测
• 新兴市场新型照护现场分子诊断的监管核准趋势

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 结核病诊断产品市场

• 消耗品
  • 套件
  • 试剂
• 装置

9. 按技术分類的结核病诊断市场

• 分子
  • 基因型检测
  • 核酸增幅检查
• 非分子
  • 影像学
  • 免疫学检测

第十章 依检测类型分類的结核病诊断市场

• 检测测试
  • 血液检查
  • 培养试验
  • 分子检测
  • 皮肤测试
  • 涂片显微镜检查
• 药物敏感性试验
  • 分子Dst
  • 表型 Dst

第十一章 结核病诊断市场（以最终用户划分）

• 诊所
• 医院
• 参考实验室

第十二章 按应用分類的结核病诊断市场

• 活动性结核病
  • 肺外结核病
  • 肺结核
• 潜伏性结核病

13. 各地区结核病诊断市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 结核病诊断市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 各国结核病诊断市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Cepheid, Inc.
  • Becton, Dickinson and Company
  • Hain Lifescience GmbH
  • Molbio Diagnostics Private Limited
  • bioMerieux SA
  • Abbott Molecular Inc.
  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics International AG
  • QIAGEN NV
  • Hologic, Inc.

The Tuberculosis Diagnostics Market is projected to grow by USD 4.93 billion at a CAGR of 5.65% by 2032.

A focused introduction that frames contemporary clinical, laboratory, and policy drivers shaping tuberculosis diagnostics and decision-making across healthcare systems

Tuberculosis remains a critical public health challenge that demands a coordinated diagnostic response across clinical, laboratory, and public health systems. The diagnostic landscape encompasses a broad array of technologies, specimen workflows, and end users, each of which influences clinical decision-making and patient outcomes. As diagnostic tools evolve, stakeholders from clinicians to reference laboratories must navigate changing regulatory environments, supply chain dynamics, and shifting disease epidemiology. Consequently, a concise synthesis of current trends and strategic implications supports more informed resource allocation and technology adoption choices.

This executive summary synthesizes cross-cutting themes that shape diagnostic practice and procurement, emphasizing technological advances, operational bottlenecks, and policy drivers. It also highlights segmentation-specific considerations that affect procurement cycles and clinical utility, spanning consumables through instruments and molecular through nonmolecular platforms. By framing these insights within contemporary clinical priorities, the narrative informs leaders who are responsible for deploying diagnostics at scale and integrating them into broader care pathways. Moving from descriptive context to strategic implications, the summary outlines how organizations can align investments with evolving diagnostic needs while maintaining patient-centered outcomes and system resilience.

How rapid molecular innovation, digital imaging advances, and system interoperability are reshaping tuberculosis diagnostics and clinical pathways in practice

The diagnostic landscape for tuberculosis is undergoing a series of transformative shifts driven by technological innovation, evolving clinical priorities, and operational modernization. Molecular techniques, particularly rapid nucleic acid amplification tests and genotypic assays, have moved from specialized reference settings toward more decentralized use, reducing time-to-result and enabling earlier therapeutic decisions. At the same time, nonmolecular modalities such as digital radiography augmented with artificial intelligence and improved immunological assays continue to refine case-finding and triage strategies, enabling a more layered diagnostic pathway that balances sensitivity, specificity, and resource constraints.

Concurrently, integration trends are changing how diagnostics are delivered within health systems. Laboratories increasingly emphasize interoperability with electronic medical records and laboratory information systems, while point-of-care deployments prioritize ease of use and connectivity for remote monitoring. These shifts are complemented by policy and programmatic changes that prioritize rapid detection of drug-resistant strains, improve linkage-to-care, and support active case finding in high-burden populations. As a result, healthcare providers and procurement teams face new decisions about technology mix, training needs, and long-term operational sustainability, prompting a re-evaluation of investment priorities and implementation roadmaps.

Assessing the cumulative operational and procurement ramifications of United States tariffs introduced in 2025 on diagnostics sourcing, supply chain resilience, and vendor strategies

The introduction of tariffs and trade policy adjustments in 2025 has influenced procurement strategies, supplier selection, and component sourcing within the diagnostics value chain. Tariff pressures tend to increase landed costs for imported instruments and consumables, prompting laboratory managers and procurement officers to reassess vendor contracts and consider alternative sourcing strategies. In response, many stakeholders have explored regional suppliers, long-term supplier agreements, and increased inventory buffers to mitigate the risk of cost volatility and shipment delays.

Moreover, tariffs can accelerate supplier diversification and local manufacturing initiatives as manufacturers seek to minimize exposure to trade barriers. This shift may alter supply networks over time and encourage investment in manufacturing capabilities closer to demand centers. Simultaneously, regulatory authorities and purchasers have placed greater emphasis on supply chain transparency, contract flexibility, and contingency planning to maintain continuity of diagnostic services. Collectively, these developments underscore the need for procurement teams and corporate strategists to incorporate trade policy scenarios into operational planning while preserving clinical performance and timely access to diagnostic tools.

Detailed segmentation analysis linking product types, technology classes, test purposes, end-user settings, and clinical applications to procurement and operational strategies

Understanding segmentation is essential for aligning product strategy with clinical utility and procurement cycles. Based on product, the market spans consumables and instruments, with consumables comprising kits and reagents whose recurring nature drives ongoing purchasing decisions and cold-chain logistics. Instruments require capital planning, installation, and maintenance programs, and therefore procurement choices often reflect longer-term clinical workflows and service agreements. This product-level differentiation also influences supplier contracts, warranty structures, and training commitments.

Based on technology, the landscape divides into molecular and nonmolecular approaches. Molecular technologies include genotypic assays and nucleic acid amplification tests that excel in rapid detection and resistance profiling, while nonmolecular approaches encompass imaging modalities and immunological assays that support screening, triage, and latent infection assessment. Each technology pathway has distinct operational characteristics relating to sample handling, throughput, and laboratory biosafety requirements. Based on test type, diagnostics are categorized into detection tests and drug susceptibility testing. Detection tests include blood tests, culture-based tests, molecular tests, skin tests, and smear microscopy; they guide initial diagnosis and case identification. Drug susceptibility testing is further distinguished into molecular DST and phenotypic DST, both of which are critical for informing effective treatment regimens and public health containment strategies.

Based on end user, deployment considerations vary across clinics, hospitals, and reference laboratories. Clinics often prioritize ease of use and rapid turnaround to support point-of-care decisions, hospitals balance throughput and comprehensive reporting for inpatient care, and reference laboratories handle complex assays and confirmatory testing. Based on application, the diagnostic pathway differentiates between active tuberculosis and latent tuberculosis, where active disease further segments into extrapulmonary and pulmonary presentations; these clinical distinctions dictate specimen types, diagnostic algorithms, and downstream clinical management. Taken together, these segmentation lenses inform procurement priorities, capacity planning, and clinical integration strategies that stakeholders must reconcile when designing diagnostic networks.

Comparative regional perspectives on diagnostic access, implementation priorities, and capacity-building imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape diagnostic availability, adoption patterns, and implementation priorities across geographies. In the Americas, strong laboratory infrastructure in many urban centers enables adoption of rapid molecular diagnostics and integration with electronic health records, while outreach to underserved and rural communities emphasizes point-of-care technologies and mobile screening initiatives. Meanwhile, programmatic priorities increasingly address the intersection of tuberculosis with comorbidities and vulnerable populations, which influences specimen referral networks and clinician training programs.

In Europe, Middle East & Africa, heterogeneous health system capacity drives a mixed-pace adoption pattern where advanced centralized laboratories coexist with resource-constrained peripheral sites. This region places high importance on capacity-building, procurement collaborations, and regulatory alignment to ensure quality and consistency across borders. Investments in decentralization are balanced against the need to maintain quality assurance and confirmatory testing pathways. In the Asia-Pacific, high-burden settings have catalyzed rapid uptake of point-of-care molecular diagnostics, strengthened laboratory networks, and prioritized strategies for drug-resistant tuberculosis. Regional manufacturers and public-private partnerships play a significant role in scaling access, while digital health initiatives and community-based screening programs complement diagnostic investments. Across regions, cross-cutting themes such as supply chain resilience, workforce development, and the harmonization of diagnostic algorithms remain central to successful implementation.

Company-level dynamics highlighting strategic partnerships, technological specialization, and the operational capabilities that drive diagnostic adoption and sustainability

A mix of established multinational diagnostic manufacturers and specialized innovators drives technological progress and market dynamics. Manufacturers of molecular platforms have prioritized assay expansion, throughput enhancement, and connectivity features to meet the needs of diverse laboratory footprints. Simultaneously, companies focused on consumables and reagents emphasize quality control, lot-to-lot consistency, and logistical reliability to support uninterrupted testing programs. There is also a notable rise in specialized firms developing targeted assays for drug resistance markers and rapid susceptibility profiling, responding to clinical demand for faster therapeutic guidance.

Strategic partnerships between instrument providers and reagent suppliers have become more common, as they streamline procurement and service delivery for health systems. Innovators in digital radiography and artificial intelligence have pursued integrations with laboratory workflows to improve triage efficiency, while contract service providers and maintenance networks play an important role in sustaining equipment uptime, particularly in decentralized settings. Across the competitive landscape, companies that demonstrate robust regulatory compliance, dependable supply chains, and scalable training models tend to achieve wider clinical adoption. Looking ahead, collaboration between diagnostics developers, clinical researchers, and implementation partners will be essential to translate technical advances into routine clinical practice and public health impact.

Actionable strategic imperatives for diagnostics leaders to strengthen portfolios, supply chains, workforce capability, data integration, and stakeholder partnerships

Industry leaders should adopt a multi-pronged strategy that balances innovation, operational resilience, and stakeholder engagement. First, prioritize modular technology portfolios that allow rapid adaptation to changing clinical needs without requiring complete platform replacement. This approach reduces obsolescence risk and enables laboratories to scale specific assays as clinical demand evolves. Second, strengthen supply chain visibility by formalizing multi-supplier agreements, regional stocking strategies, and service-level commitments to reduce vulnerability to trade disruptions and component shortages.

Third, invest in workforce development and remote-support capabilities to ensure that technicians and clinicians can effectively use advanced diagnostics, interpret complex results, and maintain quality standards. Fourth, pursue interoperability and data integration initiatives that tie diagnostics into broader care pathways, enabling faster clinical action and improved surveillance. Fifth, engage proactively with regulatory bodies and payors to clarify reimbursement pathways and evidence requirements that support adoption. Finally, cultivate collaborative partnerships with public health programs and community providers to align diagnostic deployment with screening, contact tracing, and treatment-support strategies. Together, these steps will position organizations to respond nimbly to both clinical imperatives and operational challenges.

A transparent, multi-source research methodology integrating stakeholder interviews, clinical evidence, regulatory guidance, and supply chain assessments to validate insights

The research synthesized here draws on a structured and transparent methodology that integrates multiple evidence streams to support robust insight development. Primary inputs include stakeholder interviews with laboratory directors, clinicians, procurement officers, and manufacturer representatives, which provide first-hand perspectives on operational challenges and adoption drivers. These qualitative insights are complemented by systematic reviews of peer-reviewed clinical literature, technical guidance from authoritative public health agencies, and regulatory approvals that contextualize technology performance and intended use.

Additionally, the approach incorporates supply chain analysis and procurement practice reviews to assess sourcing vulnerabilities and logistical considerations. Comparative technology assessments evaluate assay performance characteristics, sample handling requirements, and implementation complexity to inform deployment scenarios. Throughout the research process, triangulation across data types ensured consistency of findings and highlighted areas of divergence for further exploration. Emphasis was placed on reproducibility of methods, explicit documentation of assumptions, and validation of insights with subject-matter experts to ensure practical relevance for decision-makers.

A succinct conclusion emphasizing the convergence of technology advances, operational resilience, and collaborative implementation to improve tuberculosis diagnostic outcomes

In synthesis, tuberculosis diagnostics are at an inflection point where technological advancements, regional implementation dynamics, and supply chain considerations converge to redefine diagnostic pathways. Molecular and nonmolecular technologies complement one another, enabling a layered approach to detection, triage, and resistance profiling that can improve clinical outcomes when integrated thoughtfully into care systems. At the same time, procurement strategies and operational practices must adapt to geopolitical developments and evolving demand patterns to preserve timely access to essential diagnostics.

Consequently, stakeholders who combine a strategic focus on adaptable technology portfolios, robust supply chain planning, workforce capacity-building, and regional implementation alignment will be best positioned to translate diagnostic innovation into sustained clinical and public health impact. Continued collaboration among manufacturers, health systems, and public health authorities will be critical to ensure that technological promise results in measurable improvements in diagnosis, treatment initiation, and containment of drug-resistant tuberculosis.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of CRISPR-based point-of-care assays for rapid tuberculosis detection
• 5.2. Expansion of AI-enhanced imaging technologies for automated sputum smear analysis in TB screening
• 5.3. Scaling up portable molecular diagnostic platforms to enable community-based TB screening in remote areas
• 5.4. Adoption of multiplexed nucleic acid amplification tests for drug resistant TB detection worldwide
• 5.5. Emergence of next generation sequencing for comprehensive resistance profiling and epidemiological tracing
• 5.6. Development of breath based volatile organic compound sensors for non invasive TB screening at point of care
• 5.7. Integration of digital health platforms with diagnostics for real time TB case monitoring and management
• 5.8. Government subsidy programs driving adoption of rapid molecular TB tests in high burden regions
• 5.9. Strategic partnerships between diagnostic manufacturers and NGOs to accelerate low cost TB test distribution
• 5.10. Trend of regulatory approvals for novel point of care TB molecular diagnostics in emerging markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Diagnostics Market, by Product

• 8.1. Consumables
  • 8.1.1. Kits
  • 8.1.2. Reagents
• 8.2. Instruments

9. Tuberculosis Diagnostics Market, by Technology

• 9.1. Molecular
  • 9.1.1. Genotypic Assays
  • 9.1.2. Nucleic Acid Amplification Tests
• 9.2. Nonmolecular
  • 9.2.1. Imaging
  • 9.2.2. Immunological Assays

10. Tuberculosis Diagnostics Market, by Test Type

• 10.1. Detection Test
  • 10.1.1. Blood Tests
  • 10.1.2. Culture-Based Tests
  • 10.1.3. Molecular Tests
  • 10.1.4. Skin Tests
  • 10.1.5. Smear Microscopy
• 10.2. Drug Susceptibility Testing
  • 10.2.1. Molecular Dst
  • 10.2.2. Phenotypic Dst

11. Tuberculosis Diagnostics Market, by End User

• 11.1. Clinics
• 11.2. Hospitals
• 11.3. Reference Laboratories

12. Tuberculosis Diagnostics Market, by Application

• 12.1. Active Tb
  • 12.1.1. Extrapulmonary Tb
  • 12.1.2. Pulmonary Tb
• 12.2. Latent Tb

13. Tuberculosis Diagnostics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Tuberculosis Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Tuberculosis Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Cepheid, Inc.
  • 16.3.2. Becton, Dickinson and Company
  • 16.3.3. Hain Lifescience GmbH
  • 16.3.4. Molbio Diagnostics Private Limited
  • 16.3.5. bioMerieux SA
  • 16.3.6. Abbott Molecular Inc.
  • 16.3.7. Thermo Fisher Scientific Inc.
  • 16.3.8. Roche Diagnostics International AG
  • 16.3.9. QIAGEN N.V.
  • 16.3.10. Hologic, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GENOTYPIC ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CULTURE-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SMEAR MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR DST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PHENOTYPIC DST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY EXTRAPULMONARY TB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PULMONARY TB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LATENT TB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 308. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 309. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 310. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 311. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. MIDDLE EAST TUBERCULOS